FDA approves drug to treat Duchenne muscular dystrophy - FDA Press Releases

The U.S. Food and Drug Administration today approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system.

from Food and Drug Administration--Press Releases http://ift.tt/2loP5D2
via IFTTT